Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery
Pharmaceuticals · 15.04.2023 · 16 (4) · 598
DOI: 10.3390/ph16040598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 15.04.2023. Verfasst von Jie Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biology, Leiden University, 2333 BE Leiden, The Netherlands. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
Uveal melanoma (UM) is a rare malignant cancer of the eye, with up to 50% of patients dying from metastasis, for which no effective treatment is available. Due to the rarity of the disease, there is a great need to harness the limited material available from primary tumors and metastases for advanced research and preclinical drug screening. We established a platform to isolate, preserve, and transiently recover viable tissues, followed by the generation of spheroid cultures derived from primary UM. All assessed tumor-derived samples formed spheroids in culture within 24 h and stained positive for melanocyte-specific markers, indicating the retention of their melanocytic origin. These short-lived spheroids were only maintained for the duration of the experiment (7 days) or re-established from frozen tumor tissue acquired from the same patient. Intravenous injection of fluorescently labeled UM cells derived from these spheroids into zebrafish yielded a reproducible metastatic phenotype and recapitulated molecular features of the disseminating UM. This approach allowed for the experimental replications required for reliable drug screening (at least 2 individual biological experiments, with n > 20). Drug treatments with navitoclax and everolimus validated the zebrafish patient-derived model as a versatile preclinical tool for screening anti-UM drugs and as a preclinical platform to predict personalized drug responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biology, Leiden University, 2333 BE Leiden, The Netherlands.
- Liverpool Ocular Oncology Research Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3BX, UK.
- Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
- Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
- Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
ORCID-Profile: Jie Yin, Sarah E Coupland, Aart G Jochemsen, Gabriel Forn-Cuní, Annemijn P A Wierenga, Martine J Jager
Förderung
- European Union’s Horizon 2020 research and innovation program
Zitieren
APA
Yin, J., Zhao, G., Kalirai, H., Coupland, S. E., Jochemsen, A. G., Forn-Cuní, G., Wierenga, A. P. A., Jager, M. J., Snaar-Jagalska, B. E., & Groenewoud, A. (2023). Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery. Pharmaceuticals, 16(4), 598. https://doi.org/10.3390/ph16040598
Vancouver
Yin J, Zhao G, Kalirai H, Coupland SE, Jochemsen AG, Forn-Cuní G, et al. Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery. Pharmaceuticals. 2023;16(4):598. doi:10.3390/ph16040598
BibTeX
@article{Yin2023,
author = {Yin, Jie and Zhao, Gangyin and Kalirai, Helen and Coupland, Sarah E and Jochemsen, Aart G and Forn-Cuní, Gabriel and Wierenga, Annemijn P A and Jager, Martine J and Snaar-Jagalska, B Ewa and Groenewoud, Arwin},
title = {Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {4},
pages = {598},
doi = {10.3390/ph16040598}
}
EUVIMED